Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Contact Us

To learn more about Avalanche and our therapies for treating eye-related diseases, contact us.

Avalanche Biotechnologies
1035 O’Brien Drive, Suite A
Menlo Park, CA 94025

Tel: 650-272-6269
Fax: 650-362-1908

Email:

General Inquiry: info@avalanchebiotech.com
Careers: careers@avalanchebiotech.com
Business Development: busdev@avalanchebiotech.com


Or Submit This Contact Form:

Send To:
First Name:*
Last Name:*
Title:
Company Name:*
E-mail Address:*
Phone Number:
Message:*
 

Avalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

May 14, 2015

MENLO PARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need, announced that three posters, including one providing baseline demographics and characteristics from its Phase 2a clinical trial for AVA-101, will be presented at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting in New Orleans.

Read More

Read All Avalanche News